152 related articles for article (PubMed ID: 26256870)
21. Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer.
Barbui T; Gavazzi A; Sciatti E; Finazzi MC; Ghirardi A; Carioli G; Carobbio A
Curr Hematol Malig Rep; 2023 Aug; 18(4):105-112. PubMed ID: 37221411
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic dysregulation of hematopoietic stem cells and preleukemic state.
Kunimoto H; Nakajima H
Int J Hematol; 2017 Jul; 106(1):34-44. PubMed ID: 28555413
[TBL] [Abstract][Full Text] [Related]
23. [Effect of mutation on diagnosis, risk stratification, and treatment decisions in Philadelphia-negative myeloproliferative neoplasms].
Kirito K
Rinsho Ketsueki; 2017; 58(10):1931-1940. PubMed ID: 28978835
[TBL] [Abstract][Full Text] [Related]
24. The JAK2 46/1 haplotype does not predispose to CALR-mutated myeloproliferative neoplasms.
Soler G; Bernal-Vicente A; Antón AI; Torregrosa JM; Caparrós-Pérez E; Sánchez-Serrano I; Martínez-Pérez A; Sánchez-Vega B; Vicente V; Ferrer-Marin F
Ann Hematol; 2015 May; 94(5):789-94. PubMed ID: 25482455
[TBL] [Abstract][Full Text] [Related]
25. Role of TET2 mutations in myeloproliferative neoplasms.
Pronier E; Delhommeau F
Curr Hematol Malig Rep; 2012 Mar; 7(1):57-64. PubMed ID: 22200996
[TBL] [Abstract][Full Text] [Related]
26. MiR-10a and HOXB4 are overexpressed in atypical myeloproliferative neoplasms.
Dumas PY; Mansier O; Prouzet-Mauleon V; Koya J; Villacreces A; Brunet de la Grange P; Luque Paz D; Bidet A; Pasquet JM; Praloran V; Salin F; Kurokawa M; Mahon FX; Cardinaud B; Lippert E
BMC Cancer; 2018 Nov; 18(1):1098. PubMed ID: 30419846
[TBL] [Abstract][Full Text] [Related]
27. Mechanisms of mutations in myeloproliferative neoplasms.
Levine RL
Best Pract Res Clin Haematol; 2009 Dec; 22(4):489-94. PubMed ID: 19959098
[TBL] [Abstract][Full Text] [Related]
28. Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives.
Vannucchi AM; Guglielmelli P; Rambaldi A; Bogani C; Barbui T
J Cell Mol Med; 2009 Aug; 13(8A):1437-50. PubMed ID: 19522842
[TBL] [Abstract][Full Text] [Related]
29. Genetic and epigenetic complexity in myeloproliferative neoplasms.
Cross NC
Hematology Am Soc Hematol Educ Program; 2011; 2011():208-14. PubMed ID: 22160036
[TBL] [Abstract][Full Text] [Related]
30. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
31. JAK2 mutations and clinical practice in myeloproliferative neoplasms.
Tefferi A
Cancer J; 2007; 13(6):366-71. PubMed ID: 18032973
[TBL] [Abstract][Full Text] [Related]
32. [Molecularly pathogenesis and molecular targeted therapy for myeloproliferative neoplasms].
Shide K
Rinsho Ketsueki; 2015 Feb; 56(2):150-8. PubMed ID: 25765794
[TBL] [Abstract][Full Text] [Related]
33. [Mutations of epigenetic regulator genes and myeloid malignancies].
Muto T; Sashida G; Oshima M; Iwama A
Rinsho Ketsueki; 2015 Nov; 56(11):2287-94. PubMed ID: 26666714
[TBL] [Abstract][Full Text] [Related]
34. A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression.
Marty C; Lacout C; Droin N; Le Couédic JP; Ribrag V; Solary E; Vainchenker W; Villeval JL; Plo I
Leukemia; 2013 Nov; 27(11):2187-95. PubMed ID: 23558526
[TBL] [Abstract][Full Text] [Related]
35. MPL mutation profile in JAK2 mutation-negative patients with myeloproliferative disorders.
Ma W; Zhang X; Wang X; Zhang Z; Yeh CH; Uyeji J; Albitar M
Diagn Mol Pathol; 2011 Mar; 20(1):34-9. PubMed ID: 21326037
[TBL] [Abstract][Full Text] [Related]
36. Multiplex CRISPR/Cas9-Based Genome Editing in Human Hematopoietic Stem Cells Models Clonal Hematopoiesis and Myeloid Neoplasia.
Tothova Z; Krill-Burger JM; Popova KD; Landers CC; Sievers QL; Yudovich D; Belizaire R; Aster JC; Morgan EA; Tsherniak A; Ebert BL
Cell Stem Cell; 2017 Oct; 21(4):547-555.e8. PubMed ID: 28985529
[TBL] [Abstract][Full Text] [Related]
37. Thrombosis in myeloproliferative neoplasms with JAK2V617F mutation.
Sun T; Zhang L
Clin Appl Thromb Hemost; 2013; 19(4):374-81. PubMed ID: 22826442
[TBL] [Abstract][Full Text] [Related]
38. A primer on genomic and epigenomic alterations in the myeloproliferative neoplasms.
Rampal R; Levine RL
Best Pract Res Clin Haematol; 2014 Jun; 27(2):83-93. PubMed ID: 25189720
[TBL] [Abstract][Full Text] [Related]
39. Genetics of myeloproliferative neoplasms.
Viny AD; Levine RL
Cancer J; 2014; 20(1):61-5. PubMed ID: 24445766
[TBL] [Abstract][Full Text] [Related]
40. JAK2 and MPL mutations in myeloproliferative neoplasms.
Koppikar P; Levine RL
Acta Haematol; 2008; 119(4):218-25. PubMed ID: 18566540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
